Starpharma Holdings Limited (ASX:SPL)
Australia
· Delayed Price · Currency is AUD | Market Cap | 296.91M |
| Revenue (ttm) | 14.58M |
| Net Income (ttm) | -3.23M |
| Shares Out | 421.15M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,116,717 |
| Average Volume | 2,117,229 |
| Open | 0.700 |
| Previous Close | 0.705 |
| Day's Range | 0.690 - 0.735 |
| 52-Week Range | 0.082 - 0.750 |
| Beta | 0.48 |
| RSI | 72.45 |
| Earnings Date | May 18, 2026 |
About Starpharma Holdings
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance... [Read more]
Financial Performance
In fiscal year 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.
Financial StatementsNews
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC).
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia , Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & D...
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® c...
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 mil...
Starpharma signs DEP® ADC Research Agreement with MSD
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth...
Starpharma to Webcast Live at Life Sciences Investor Forum September 17th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com Company invites individual and...
Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma’s SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Starpharma creates slow release soluble DEP remdesivir nanoparticle
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma creates slow release soluble DEP® remdesivir nanoparticle
Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update
MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma SPL7013 nasal spray for COVID-19 – development update